Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: Timing and specimen types

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1162-1168

  Loi, Sherene ^a   Symmans, W Fraser ^b   Bartlett, John MS ^c   Fumagalli, Debora ^a   Veer, Laura Van't ^d   Forbes, John F ^f   Bedard, Philippe ^g   Denkert, Carsten ^h   Zujewski, JoAnne ⁱ   Viale, Giuseppe ^j   Pusztai, Lajos ^b   Esserman, Laura J ^e   Leyland Jones, Brian R ^k  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN;

BIOPSY TECHNIQUE; BIOSPECIMEN COLLECTION; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER TISSUE; CLINICAL TRIAL (TOPIC); EMBEDDING; GENERAL AND MISCELLANEOUS PROCEDURES AND TECHNIQUES; HEALTH CARE ORGANIZATION; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; NOTE; PATIENT PARTICIPATION; PATIENT REFERRAL; PLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SERUM; STANDARDIZATION; TISSUE FIXATION;

BIOPSY; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOADJUVANT THERAPY; PARAFFIN EMBEDDING; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; SPECIMEN HANDLING; TIME FACTORS; TISSUE FIXATION;

EID: 81255168064     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70117-6     Document Type: Note

References (24)

1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, 30:96-102.
2. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
3. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027.
4. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009, 20:1948-1952.
5. Lebeau A, Turzynski A, Braun S, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 2010, 28:3264-3270.
6. Gong Y, Yan K, Lin F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007, 8:203-211.
7. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100:1380-1388.
8. Baselga J, Bradbury I, Eidtmann H, et al, on behalf of the NeoALTTO Study Team. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium; Dec 8-12, 2010; San Antonio, TX, USA: abstr S3-3.
9. Esserman LJ, Perou C, Cheang M, et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY trial (CALGB 150007/150012, ACRIN 6657). Proc Am Soc Clin Oncol 2009, 27(suppl 18s). for the I-SPY Investigators, abstr LBA515.
10. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170.
11. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000, 6:4610-4617.
12. Dowsett M, Smith IE, Ebbs SR, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 2006, 12(3 Pt 2):1024s-1030s.
13. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25:4414-4422.
14. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003, 97:2960-2971.
15. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003, 9:2406-2415.
16. Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010, 28:4316-4323.
17. Helbich TH, Matzek W, Fuchsjager MH Stereotactic and ultrasound-guided breast biopsy. Eur Radiol 2004, 14:383-393.
18. Leyland-Jones BR, Ambrosone CB, Bartlett J, et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol 2008, 26:5638-5644.
19. Roepman P, Schuurman A, Delahaye LJMJ, Witteveen AT, Floore AN, Glas AM A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility. BMC Med Genomics 2009, 2:52.
20. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7.
21. Barry WT, Kernagis DN, Dressman HK, et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 2010, 28:2198-2206.
22. Lyng MB, Laenkholm AV, Pallisgaard N, et al. Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array. Cell Oncol 2007, 29:361-372.
23. Swanton C, Burrell RA, Futreal PA Breast cancer genome heterogeneity: a challenge to personalised medicine?. Breast Cancer Res 2011, 13:104.
24. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006, 94:524-531.